From pathophysiology to clinical benefits: what new combinations of a statin and antihypertensive drugs can provide


Professor Claudio Borghi shows the ‘‘state of the art’’ of hypertension and hypercholesterolemia treatment and control. Analysing the ESC guidelines and several clinical studies, the use of statins, ACE inhibitors (ACEi) and calcium channel blockers (CCB) emerges as the treatment of choice in patients with hypertension (HTN) and dyslipidemia. In fact:

  • The benefit of using statins in HTN patients is not limited only on atherosclerosis prevention, but also on blood pressure control improvement.
  • According to a pathophysiological link involving renin-angiotensin-aldosterone system, LDL-C and vascular Ca2+, HTN and dyslipidemia can synergistically contribute to atherosclerosis and CV disease management.
  • A treatment strategy based on statins, ACEi and CCB has proven to be the most effective in randomised controlled trials about HTN and dyslipidemia.
  • The impact of combined treatment increases by improving individual drug adherence with single-pill combinations.

This video is part of the session “Tackling cardiovascular diseases with a new generation of polypills” held virtually at ESC Congress 2020 on Monday August 31st, 2020, with chairperson Charalambos Vlachopoulos (Greece).

View also the other parts of the congress session: